Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor

BACKGROUND: Androgen ablation is one of the viable therapeutic options for patients with primary hormone (androgen)-dependent prostate cancer. However, an antibiotic brefeldin A (BFA) has been shown to exhibit the growth inhibitory effect on human cancer cells. We thus investigated if BFA might inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajamahanty, Srinivas, Alonzo, Catherine, Aynehchi, Shahrad, Choudhury, Muhammad, Konno, Sensuke
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843609/
https://www.ncbi.nlm.nih.gov/pubmed/20102617
http://dx.doi.org/10.1186/1423-0127-17-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843609/
https://www.ncbi.nlm.nih.gov/pubmed/20102617
http://dx.doi.org/10.1186/1423-0127-17-5

Ejemplares similares